Watchlist 12/13/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist:  $PYDS, $GLBR, $PRELF (OTC),

 

PYDS: Float of 5.92 million shares with 3.31% short.  

Stock price has been rising ever since the company filed its Form 8-K.  In addition, many technical indicators on the Daily Chart are showing a bullish signal.  

pyds.png

GLBR: Float of 4.8 million shares with 9.65% short.

Global Brokerage, Inc. Receives Approximately 78.5% Yes Votes to Move Forward with the Prepackaged Plan of Reorganization.  Global Brokerage has filed a voluntary petition for reorganization under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York. The bankruptcy case is expected to take no longer than sixty days. All voting creditors voted in favor of the Plan.  The overall purpose of the Plan is to enable Global Brokerage to exchange the Current Notes for new notes that have a five-year extended maturity and to restructure its current operations to reduce current expenses.

glbr.png

PRELF: Float of 151.49 million shares.

Blockchain stocks still riding the wave of Bitcoin and other Cryptocurrencies.  BTC Futures are over $17K at this point. PRELF showing strong technical momemtum.

prelf.png

 

 

Watchlist 12/12/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist:  $BTCS, $RIOT, $MARA (Short), $ADMP

BTCS: Float of 241.39 million shares.  Many Blockchain stocks were flying on Monday.  I expect this to continue.  Have a look at the BTCS chart for technical analysis.

The first day of bitcoin futures trading on the CBOE exchange is over and the day largely went according to plan, according to its CEO. Overall, Monday saw the price of bitcoin push above $17,000 on CoinDesk's Bitcoin Price Index (BPI) to hit a new all-time high in the hours after the Chicago-based firm began trading the derivatives. That process began late Sunday, an event that coincided with a near-simultaneous crashing of CBOE's website.  The price of bitcoin jumped over $1,000 in minutes.  Reports indicate, however, that trading has gone relatively smoothly since then.

btcs.png

RIOT: Float of 4.32 million shares with 20.36% short.

Riot Blockchain Inc. today announced that its majority owned Tess Inc. has entered into a non-binding letter of intent to merge with Cresval Capital Corp. (TSX-V: CRV). TessPay is a blockchain company developing a supply chain payment platform for businesses to attempt to guarantee payment on time and in full.  After the closing of the anticipated merger, TessPay will be publically traded on the TSX Venture Exchange (the "TSXV") and change its name to "TessPay Inc.".  The merger would be the first of Riot Blockchain's investments to become a stand-alone public company.  Jeff Mason, Chief Executive Officer of TessPay, stated, "The decision to take the company public provides us access to traditional capital markets as we continue developing our blockchain technology solution. This environment will also foster transparency and accountability moving forward, providing confidence to investors and prospective customers alike."

riot.png

MARA (Short call): Float of 6.62 million shares with 8.66% short.

Shares of Marathon Patent Group Inc slumped nearly 15% to $5.35 in after-hours trading Monday, following the announcement of a dilutive equity offering.  The IP licensing firm priced 1,000,000 shares at $5.00 apiece, which is well below today's closing price of $6.30 per share. The stock's 50-day moving average is $2.39 and its 200-day moving average is $0.83.  In addition to that deep discount, the offering represents nearly 10% dilution for existing shareholders.  However, the offering did raise $5 million, which will provide the company additional liquidity to meet its working capital and general corporate cash requirements.  The shares were offered and are being sold to certain accredited investors in a registered direct offering. The offering is expected to close on or about December 14, 2017.

mara.png

ADMP:  Float of 30.30 Million shares with 7.52% short.

Adamis Pharmaceuticals Corp shares soared nearly 19% last Tuesday, after the small drug maker announced that it has submitted an investigational new drug (IND) application to the FDA to begin testing the drug compound naloxone in human patients using Symject, presumably as a reaction to the worsening opioid crisis. Adamis intends to develop a naloxone injection product candidate utilizing the same patented syringe drug delivery platform used in Symjepi.

Raymond James analyst Elliot Wilbur commented, “Although the sheer size of the naloxone market is not substantial, it continues to grow rapidly in tandem with opioid overdose prevention measures. It would be unreasonable to assume the market for naloxone agents could increase some 50%- 75% prior to an ADMP approval creating a potential significant new growth avenue for the company. We believe a Naloxone agent in a simple easy to use presentation such as Symject could conservatively present a $50-75M commercial opportunity.”

admp.png

Watchlist 12/11/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist:  $GRAM, $QURE, $FCEL, XXII

GRAM: Float of 101.75 million shares with 0.27% short.  

The substantial decrease in stock price over the past month has been due to an investigation of GRAM for alleged involvement in bribes paid to a former president by its Brazilian partner Odebrecht.  

I believe we have seen the bottom of the share price and expect it to go back up as investigation continus.

gram.png

QURE: Float of 24.14 million shares with 3.14% short.

QURE Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting over the weekend.  Non-human primate study of AMT-061 utilizing FIX-Padua shows 6.5-fold increase in FIX clotting activity compared to AMT-060.  Data supports nonclinical comparability plan agreed upon with FDA.  

“These data establish that AMT-061 is well-tolerated and provides a substantial increase in FIX activity compared to AMT-060, consistent with the gain-of-function reported in previous preclinical studies of FIX-Padua,” stated Sander van Deventer, M.D., Ph.D., chief scientific officer of uniQure.

 

qure.png

FCEL: Float of 63.6 million shares with 12.87% short.

FuelCell Energy Inc. FCEL recently inked an agreement to sell renewable hydrogen to Toyota Motor Corp. TM. This tie-up, better known as hydrogen and power off-take agreement, is in line with FuelCell’s strategy to actively market its distributed hydrogen technology. This will offer a hydrogen fueling solution for fuel cell vehicles like that of Toyota and in turn expand FuelCell Energy’s business.

Per the terms of the deal, FuelCell Energy will install a multi-megawatt SureSource fuel cell power plant at the Port of Long Beach in California. Once operational, this plant will produce 100% renewable hydrogen which will fuel Toyota’s Mirai fuel cell electric vehicles (FCEVs) as well as Heavy Duty hydrogen fuel cell class 8 trucks (Project Portal).  In California, Governor Jerry Brown announced plans to make 100,000 zero-emission freight-hauling machines operational by 2030, under his California Sustainable Freight Action Plan (according to Bloomberg). This in turn has boosted the market for fuel cell energy in the state.

fcel.png

XXII: Float of 106.37 million shares with 7.98% short.

Motley Fool names XXII as one of the top 3 stocks under $10.  

It's been a great year for 22nd Century Group. The stock has more than doubled year to date and at one point had almost tripled, making 22nd Century Group the hottest marijuana stock on the market at the time. However, a stock offering in October resulted in a significant pullback, with 22nd Century Group shares now trading at less than $2.50.

22nd Century Group is classified by many as a marijuana stock because the company has genetically engineered cannabis plants to contain no THC, which is the primary psychoactive chemical in marijuana. However, its main product is tobacco that's genetically engineered to contain very low levels of nicotine.

In July, the U.S. Food and Drug Administration announced plans to reduce tobacco-related disease and death. Those plans included a requirement that tobacco companies lower nicotine levels in cigarettes to non-addictive levels. 22nd Century Group, at least for now, is the only company with the capability to grow tobacco with nicotine levels low enough to be non-addictive.

If the FDA's plans are put into effect, 22nd Century Group stock should resume its huge momentum from earlier in 2017. There's also the possibility that the company could link up with one or more big tobacco companies even before any regulatory changes are enacted, which could also be a major catalyst for the stock.

xxii.png

Watchlist 12/07/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist:  $GOPH (OTC), $CANN (OTC), $SIGO (OTC), $TWNK

GOPH: Float of 16.12 million shares 

Gopher Protocol Inc, a company which specializes in the creation of Internet of Things (IoT) and Artificial Intelligence enabled mobile technologies, filed a Form 8-K/A that includes 2 years audited financials for the assets purchased on September 1, 2017.  Its strategy is to "marry” the two arms of the Company – IoT and Artificial Intelligence enabled mobile technologies together with the UGO HUB. The strategy includes creating and delivering a suite of Internet of Things (IoT) technologies that ultimately increase the quality of life for all of the consumers that are within the network that is being built.   One of the main reasons Gopher Protocol pursued and acquired the assets of RWJ Advanced Marketing, previously owned by W.L. Petrey, was to roll out its proprietary technology to create a network across the United States.

goph.png

CANN: Float of 15.04 million shares.  

Wall St Journal news release on Monday: The Legal Cannabis Market is Expected to Grow Globally 

cann.png

SIGO: No float available.

The latest catalyst was on October 10th.  That marked near the bottom of the U-pattern.

Oct 10th:  SIGO turning heads recently is Sunset Island Group, Inc, which is establishing a cannabis growing facility in California. The stock rallied from $0.10 to $2.10 in the last two months - a 2000% gain - as the company made a few unique announcements - for instance, locking up 90% of their outstanding shares. Their 22,000 sq. ft. leased green house space in Northern California has been approved for cultivation, and the company is considering further expansion as they prepare to begin generating revenue in the coming year. 

sigo.png

TWNK: Float of 90.77 million shares with 14.28% short.

Hostess CEO, William Toler, has bought $2.5 million in shares this year, including the day after Thanksgiving.  On November 24th, he bought 50,000 shares of TWNK at an average price of $12.88 a share. The total cost of this purchase was $644,000.  

twnk.png

Watchlist 12/06/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include:  $GTE, $CUR, $BIOC, $BNED, $LE

GTE: Float of 367.18 million shares with 1.33% short.  Stock price is up nicely since the November 28th NR that GTE, a company focused on oil and gas exploration and production in Colombia, has reached new milestones in the Middle Magdalena Valley Basin ("MMV") during November 2017. In August 2016, Gran Tierra expanded into the MMV through the acquisition of PetroLatina Energy Limited. After little more than a year, the MMV assets, and in particular the Acordionero field, have become a significant part of the Company's portfolio and growth. Highlights include:

• Record Production - Since acquiring the Acordionero field in the MMV in August 2016, Gran Tierra has increased its production by 225% to a record high average rate of 15,358 barrels of oil per day ("bopd") (average from November 15 to 27, 2017)

• Free Cash Flow - From the acquisition date of August 23, 2016, until September 30, 2017, the MMV assets have generated $116 million in oil and natural gas sales and $85 million of operating netback1, while the Company made capital investments of $66 million; these assets have generated free cash flow during today's low oil price environment

• Drilling Efficiency - Cumulative average 46% drilling cost savings and 35% faster drilling times since acquisition in August 2016

• Diversification - The MMV assets now account for approximately 46% of Gran Tierra's total production

• Reservoir Quality - Since the acquisition, Gran Tierra has drilled, completed and brought on production 10 Acordionero oil wells which have demonstrated better than expected reservoir quality and thickness, higher than expected initial oil rates per well and increasing oil quality higher in the reservoir structure

• Enhanced Oil Recovery ("EOR") - Gran Tierra's plans for early optimization and EOR are underway with source injection water identified, pilot water injection wells drilled and tested and the waterflood pilot has commenced

gte.png

CUR: Float of 12.51 million shares with 5.91% short.  Trades almost 4.5 x its float of Tuesday with a very strong finish at the HOD.  Looking for a continuation of the gap fill potentially spiking another 75% on Wednesday.  After-hours was dows 7.4%.  

Neuralstem (CUR) revealed a huge clinical win on the back of the drug maker's successful updated Phase 2 clinical data in major depressive disorder, where the company's NSI-189 asset impressed at the 56th American College of Neuropsychopharmacology (ACNP) Annual meeting.

cur.png

BIOC:  Float of 27.16 million shares with 9.67% short.  This could be hugh in the long run.  Closed near the HOD on Tuesday.

On Tuesday, BIOC announced the issuance of a key US patent covering the company's proprietary "switch-blocker" technology.  The technology enriches patient specimens for oncogene mutations of interest, resulting in ultra-high sensitivity and specificity for the detection of cancer-associated mutations. The switch blocker technology is designed to improve detection rates for these oncogenes, allowing physicians to make informed decisions for the selection of therapy and monitoring of treatment response over time for patients with cancer.

Biocept CSO Lyle Arnold commented, "The issuance of this patent signals what we believe is the first in a series of worldwide patents protecting our proprietary, highly sensitive ctDNA platform technology [...] When combined with our patents and technology related to CTC capture and analysis as well as our blood transport tubes, Biocept has significant coverage protecting all three of its core liquid biopsy technology platforms."

bioc.png

BNED: Float of 35.22 million shares with 6.69% short.  Great Earnings for Q2.  

Barnes & Noble Education, Inc. (BNED), a leading provider of educational products and services solutions for higher education and K-12 institutions, today reported sales and earnings for the second quarter for fiscal year 2018. The Company has two reportable segments: Barnes & Noble College Booksellers, LLC (“BNC”) and MBS Textbook Exchange, LLC (“MBS”).

Financial highlights for the second quarter 2018 and fiscal year to date 2018:

  • Consolidated sales of $886.9 million increased 15.1%, as compared to the prior year period; year to date consolidated sales of $1,242.6 million increased 23.0% as compared to the prior year period.
  • Consolidated second quarter GAAP net income of $48.4 million, as compared to $29.3 million in the prior year period; year to date GAAP net income of $13.6 million, as compared to $1.4 million in the prior year period.
  • Consolidated second quarter non-GAAP Adjusted EBITDA of $102.4 million, an increase of $32.0 million, as compared to the prior year period; year to date non-GAAP Adjusted EBITDA of $70.0 million, an increase of $36.1 million, as compared to the prior year period.
  • Consolidated second quarter non-GAAP Adjusted Earnings of $49.9 million, as compared to $29.7 million in the prior year period; year to date non-GAAP Adjusted Earnings of $20.1 million, as compared to $3.8 million in the prior year period.
bned.png

LE: Float of 16.16 million shares with 18.49% short.  

Lands End, the casual clothing, accessories, and footwear retailer,  reported third-quarter earnings and revenue that beat expectations. Net income totaled $162,000, or a penny per share, compared with a loss of $7.2 million, or 23 cents per share, for the same period last year. Revenue was $325.5 million for the quarter, up from $311.5 million last year. The FactSet consensus was for a loss of 4 cents per share and sales of $320.0 million.

le.png

Watchlist 12/05/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include:  $BLKCF, $CMO, $BOOT, $UEC

 

BLKCF:  Float of 21.99 million shares.  Based on TA , I'm looking for Bitcoin to make a substantial move in the next day or two as it approaches the high over the weekend. Bitcoin now bigger than Buffett, Boeing and New Zealand’s economy.

blkcf.png

CMO: Float of 94.44 million shares with 2.22% short.  

cmo.png

BOOT: Float of 12.99 million shares with 42.37% short. 

The stock has a Zack Rank #2. The Zacks Consensus Estimate for current-year earnings rose 7% over the last 30 days. Boot Barn’s expected growth rate for the current year is 10.6%, in contrast to the industry’s projected decline of 4.2%. The company’s earnings are expected to grow 20.4% next year.

boot.png

UEC: Float of 152.4 million shares with 6.54% short.

Uranium stocks are jumping today after Kazakhstan's state-owned uranium miner, Kazatomprom, announced that it will reduce output 20% for the next three years beginning in January 2018. Why is that significant? Well, Kazakhstan is by far the world's leading supplier of uranium, accounting for nearly 40% of global production. 

uec.png

Watchlist 12/01/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include:  $ACBFF, $SFUN, $SORL

ACBFF: Float of 265.56 million shares with a valuation of $2.1 billion.

Aurora Cannabis Responds to CanniMed's Adoption of Poison Pill Tactic.  

"Since launching our offer, the feedback we have received from CanniMed's shareholders has been overwhelmingly positive. Many of CanniMed's shareholders are telling us that our offer represents an excellent premium for their CanniMed shares, and clearly see the considerable upside potential by becoming Aurora shareholders," said Cam Battley, Aurora's Executive Vice President.

The actions of CanniMed's management and Board, however, seem contrary to the wishes of CanniMed shareholders. CanniMed has adopted oppressive poison pill tactics, which appear to be driven solely by entrenched self-interest, and that purposely limit their shareholders' rights and ability to choose. They are taking fundamental rights away from their shareholders. We want CanniMed shareholders to be able to make their own choice, and we remain open for discussion at any time to explain the strong merits of our Offer. CanniMed's Board and management claim they are protecting their shareholders, but their actions say the opposite."

acbff.png

SFUN: Float of 235.43 million shares with 11.19% short.  The stock price has been following a fairly stable upward channel for 4 months and is currently trading at the bottom support.  Thursday produced a nice hammer candle indicating that the bulls took over at the end of the day.  

sfun.png

SORL: Float of 7.95 million with 20.12% short.  Relative Momentum Index is very strong for this company right now.  I'm anticipating a big squeeze soon, due to the percent short,  once the volume starts to pick up.  

SORL Auto Parts, Inc. SORL, headquartered in China, specializes in the development, production and distribution of automotive brake systems and other key safety related auto parts. The company's customer base consists of original equipment manufacturers, aftermarket distributors, and international customers.  The stock has experienced solid estimate revisions. In fact, the Zacks Consensus Estimate for full-year 2017 earnings has increased 25.4% in a month’s time.

SORL also announced today it has recently won major supply contracts from the Shanghai Municipal Transportation Commission.  SORL is the exclusive supplier of electric air compressors to all buses for Shanghai's municipal bus route 71. SORL is also the exclusive supplier of electric air compressors to all buses for Shanghai's first Bus Rapid Transit ("BRT") system.  In addition to the BRT contract, there are over 2,000 public buses in Shanghai's municipal transportation system currently using electric air compressors made by SORL.

sorl.png

Watchlist 11/30/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include:  $DPW, $PZRX

DPW: Float of 10.35 million shares with 6.89% short.  The Relative Momentum Index (RMI) is still very strong on this stock on the daily chart.  

On Monday, the company, seeking to increase revenues through acquisitions and organic growth, announced that it will present at the 10th Annual LD Micro Main Event investor conference on Thursday, December 7th at 10:30 AM PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Members of the Company’s executive management team will be presenting on behalf of the company and senior management will be available for one-on-one meetings during the event. The Company looks forward to establishing new relationships and meeting current investors and associates attending the event. The Company stated it will issue an investor update before the opening of the market on the morning of December 7, 2017. Topics will include an update on revenue guidance for the quarter and 2018, a progress report on the cryptocurrency initiative by Coolisys Technologies, advances made on the MTIX $50M purchase order and the advanced technology platform and an update on Digital Power Lending.

 

dpw.png

TEUM: Float of 11.35 million shares with 13.3% short.  If it holds the MA(50), it could test the recent high again. 

TEUM, the rapidly growing mobile Cloud Communications Platform company, announced today receipt, on November 27, 2017, of notification from NYSE Regulation that the Company has regained compliance with Section 1003(a) of the NYSE American's Company Guide relating to minimum shareholders' equity.

teum.png

Watchlist 11/29/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include:  $CVO, INPX, $BIOC

CVO: Float of 6.1 million shares with 12.34% short.  Finviz target price of $10.00.  Only down 0.68% after hours.  No catalyst yet but nice momentum on Tuesday.  Note that this was also a Play of the Day on Tuesday.

cvo.png

INPX: Float of 14.93 million shares with 6.55% short.  Latest catalyst was releasing of the Q3 earning on November 20th.  

inpx.png

BIOC: Float of 27.15 million shares with 9.34% short.

Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's Liquid Biopsy Test in Immunotherapy.  Clinical validation of Biocept's novel PD-L1 test using multiple antibody clones has potential to improve detection, treatment selection, and patient monitoring with cancer immunotherapy

bioc.png

SGRY: 

Watchlist 11/28/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include:  $RXII, $ABUS, $ARWR, $FCSC

RXII: Float of 19.44 million shares with 8.67% short.

The November 13th NR continues to push this stock forward.  The company has signed a collaborative research agreement with Gustave Roussy to evaluate the potential of RXi's novel sd-rxRNA technology platform for use in cancer treatments. Gustave Roussy is a leading Comprehensive Cancer Centre in Europe.  

rxii.png

ABUS: Float of 34.76 million shares with 1.5% short.

 Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced two oral presentations and one poster presentation at HepDART 2017 being held on December 3 - 7, 2017 in Kona, Hawaii.

Presentations Include:

  • December 5, 2017, 6:50pm - 7:10pm (HST), Shifting the Tide of Drug Development Towards HBV, NASH, and HCC: Battling Giant Killers
    December 5, 2017, 3:30pm - 5:00pm (HST), Poster Session
  • December 6, 2017, 12:00pm - 12:10pm (HST), Oral Abstract Session IV
abus.png

ARWR: Float of 65.95 million shares with 4.81% short.

Arrowhead Pharmaceuticals Inc. (ARWR) will make a presentation at the 29th Annual Piper Jaffray Healthcare Conference – New York, November 28-29, 2017.  November 28, 9:30 a.m. EST – Christopher Anzalone Ph.D., Arrowhead president and chief executive officer will participate in a fireside chat presentation.

arwr.png

FCSC: Float of 14.0 million shares with 1.3% short. 

No catalyst nearby but an nice reversal underway from a major drop in price over the past two months.  Might be good for a Dead-cat bounce or potentially more.

fcsc.png

Watchlist 11/27/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include:  $BTCS, $BTSC, $TLGT  

BTCS:  Float of 89.47M shares. 

BlockChain related Investments had a major price increase on Friday.  Over the weekend, Bitcoin surged from $8,300 on November 23rd to $9,725 at the time of writing this watch list.  An increase of 17%.  I’m expecting BTCS to rocket far higher than 17% on Monday with a continuation the rest of the week.  Note the stock price crossed all major resistance points on Friday.

The total market capitalization for the cryptocurrency market has exceeded $300 billion for the first time.  Data from CoinMarketCap.com shows that the market capitalization for all cryptocurrencies is currently at roughly $300.5bn. Of that amount, bitcoin's market cap represents the lion's share, accounting for about $158 billion.  The move comes as the price of bitcoin continues its surge above $9,000, trading at roughly $9,482, according to the CoinDesk Bitcoin Price Index (BPI).  The push above $300 billion perhaps also showcases the pace at which the market has grown in recent weeks. On Nov. 3rd, the overall market capitalization rose above $200 billion for the first time. By contrast, the market crossed the $100 billion level back in June.  Other cryptocurrency market developments contributed to today's market capitalization milestone, additional data reveals.  The world's second-largest cryptocurrency, ethereum, has a press-time market capitalization of $46 billion and is currently trading at about $475, representing a price increase of more than 25% in the past week. Like bitcoin, ethereum also hit a new all-time high over the weekend.

 

btcs.png

BTSC: Float of 7 billion shares.  See comments under BTCS above.

btsc.png

TLGT:  Float of 53.02 million shares with 15.98% short.

On November 22nd, the company announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Hydrocortisone Butyrate Lotion 0.1%.  This is Teligent’s ninth approval for 2017, and its nineteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.  Based on recent QuintilesIMS Health data from September 2017, the total addressable market for this product is approximately $17.0 million.

tlgt.png

Watchlist 11/24/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include:  $AGEN, $ATHX, $ATNX

AGEN: Float of 51.27 million shares with 20.07% short.  

On Nov. 15, 2017 AGEN, an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced the receipt of a $4 million payment for the advancement of an undisclosed antibody under the license and research collaboration agreement with Merck, known as MSD outside the United States and Canada.  As previously announced, Merck is responsible for all future product development expenses for the selected antibody and Agenus is eligible to receive up to an additional $99 million in milestone payments, as well as royalties on worldwide product sales.

agen.png

ATHX: Float of 115.82 million shares with 7.55% short.  

Last week, ATHX announced that its partner, HEALIOS K.K. (“Healios”), has enrolled the first patient in its study in Japan evaluating MultiStem® cell therapy treatment of patients who have suffered an ischemic stroke (the “TREASURE” study).  The TREASURE study is designed to enroll a total of 220 patients with moderate to severe strokes and will be randomized 1:1, with patients receiving a single intravenous infusion of MultiStem or placebo within 18 to 36 hours of the onset of the stroke. 

athx.png

ATNX: Float of 33.8 million shares with 4.66% short.  

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced Johnson Lau, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 29, 2017 at 1:00 pm EST.

On Monday, ATNX announced positive interim analysis results of an Oraxol pharmacokinetic (PK) study titled “Open-label, randomized cross-over bioavailability study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors”. Patients treated with Oraxol demonstrated exposure that was comparable to IV paclitaxel and an encouraging safety profile without grade 3-4 toxicities, according to findings from this study presented at ESMO Asia 2017 in Singapore, an Annual Congress organized by the European Society for Medical Oncology. 

The Phase 3 Interim data for Oraxol for Metastatic breast cancer is due late 2017.

sc (1).png

Watchlist 11/23/2017: Happy Thanksgiving to everyone in the United States. Please note that his watchlist is for those members trading only in the Canadian Stock Markets on Thursday.

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include: VFF.TO; ACB.TO

VFF:TO   Float of 20.37 million shares. 

Nov 22nd - Village Farms International, Inc.: Leads amongst peers with strong fundamentals.  Village Farms International, Inc. has shown good performance overall, both over the last one year (at 231.03%) as well as over the last month (at 37.93%). Share price performance over the last month, though has been lower than that over the last year. But Village Farms International, Inc.’s stock has done better than its overall peer group whose performance was 16.30% over the last month.

Nov 13th - Village Farms International Reports Improved Third Quarter 2017 Financial Results and Provides Cannabis Joint Venture Update.  

  • On September 14, 2017, the application for a "second site" cultivation license under the Access to Cannabis for Medical Purposes Regulations (ACMPR) for Pure Sunfarms Corp.'s ("Pure Sunfarms") Delta facility was submitted to Health Canada. That application was subsequently accepted for review by Health Canada on September 18, 2017; and,
  • Pure Sunfarms commenced physical conversion of the 1.1 million square foot greenhouse facility in Delta, British Columbia and expects to complete conversion of the first 250,000 square foot quadrant in February 2018 such that, subject to the receipt of cultivation and sales licenses from Health Canada, it expects to begin selling dried cannabis on or before July 2018 and to have all four quadrants commercially producing in the fourth quarter of 2019.
vff.png

ACB.TO  Float of 263.6 million shares

Aurora Cannabis intends to launch takeover bid for Cannimed Therapeutics.  

acb.png

Watchlist 11/22/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include:  $IMMU, $CORI, $EKSO

IMMU: Float of 116.14 million shares with 19.91% short.  

The Company announced on November 16, 2017, the completion of the enrollment in the first of its two registrational Phase-3 clinical trials, Study BHV3000-301, to establish the safety and efficacy of orally-dosed rimegepant for the acute treatment of migraine. 

Also significant progress made toward preparing a BLA for accelerated approval of IMMU-132,  the breakthrough therapy candidate for the treatment of late-stage metastatic triple-negative breast cancer (mTNBC). IMMU-132 has shown a remarkable response rate in patients.  

Immunomedics also announced that its Board of Directors has voted to appoint Michael Pehl as President and Chief Executive Officer (“CEO”), effective December 7, 2017.  

Tthe abstract on updated results from the Phase 2 study of IMMU-132 in patients with mTNBC was accepted for an oral presentation at the 2017 San Antonio Breast Cancer symposium (SABCS) on December 5-9, 2017.  A second abstract on the Phase 3 ASCENT trial design has also been accepted for poster presentation at the same SABCS conference.

immu.png

CORI:  Float of 33.43 million shares with 5.24% short.  Biopharma company Corium International Inc reported 19% revenue growth for Q4 2017 while its loss per share narrowed to 36 cents from 42 cents.  The company also detailed a slew of upcoming catalysts, including a Dec. 26 PDUFA action date for its partner Agile Therapeutics Inc (NASDAQ: AGRX)'s Twirla, a once-weekly contraceptive.

HC Wainwright analyst Oren Livnat reviewed the results in a Thursday note. The analyst reiterated a Buy rating and a $15 price target.   Corium reported above-consensus results ahead of near-term catalysts, Livnat said in a note. The analyst delved on a slew of near-term catalysts that could support the stock, which included:

The PDUFA date for Agile's Twirla contraceptive patch, which could fetch Corium peak of revenue of $50 million per year;

Çommercial partnership for Corium's lead asset donepezil weekly patch for Alzheimer's either this year or in the first half of 2018, with the analyst estimating peak revenues of $200 million for Corium; and

Update from FDA on whether the positive pilot donepezil patch bioequivalence study would be considered as pivotal study for a NDA filing.

 

CORI.png

EKSO: Float of 23.04 million shares with 10.06% short.  This stock was on my November 13th watchlist at 1.53.  It's currently at $4.13 for a 270% gain already with more to come.  

The deal that send EKSO soaring was in providing Ford with exoskeletons for their workers to use. These exoskeletons are for the upper half of the body and provide support to employees that have to handle overhead work during vehicle assembly.

The exoskeleton from Ekso Bionics Holdings, Inc. that offers this support is the EksoVest. The purpose of this vest is to reduce the amount of fatigue and strain that Ford employees experience when doing overhead work. It will also hopefully reduce injuries as well.

EKSO.png

Watchlist 11/21/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include:  $DX, $MRDN,  $BTCS

DX: Float of 50.02 million shares with 1.69% short.  Very solid company and very strong technical chart gaining momentum. 

This mortgage real estate investment trust has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 5.9% over the last 60 days.  The company possesses a Value Score of A.

dx.png

MRDN: Float of 7.48 million shares with 1.44% short.  Meridian Waste Solutions Closes Three Acquisitions to Enhance its Technology Footprint.  Announced today the closing of the acquisitions of three companies: WelNess, LLC, LGMG, LLC (d/b/a Verifi Resource Group) and Integrity Lab Solutions, LLC, companies specializing in medical hospital laboratory testing and diagnostics operations.  

 

mrdn.png

BTCS: Float of 89.47 million shares. Lots of Bitcoin and Blockchain news in the media recently driving up prices.  See chart.

btcs.png

Watchlist 11/20/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include:  $HMNY, $CBIO , $MNKD

HMNY:  Float of 4.85 million shares with 37% short.  HMNY is just beginning to turn around in its TA but the key for HMNY is its float of 4.85 million shares with almost 37% short.  That means when the price starts rising, it will likely go up very fast just like it did in early October. 

MoviePass Could Hit 1 Million Users This Year.  MoviePass announced Thursday a new one-year promotions subscription service. According to one Wall Street analyst, Helios and Matheson Analytics Inc will ride the MoviePass wave to a higher share price in the coming year.  Maxim Group analyst Brian Kinstlinger has a Buy rating and a $25 price target for Helios stock

HMNY.png

CBIO: Float of 3.62 million shares with 11.91% short.  CBIO had a big volume days on Friday in relation to its EMA(20) volume and the momentum is also bullish at this particular point. The last big spike in price for CBIO was in late March.  

CBIO released in earnings on November 13th.   The % revenue growth YOY was 192% while the Earnings growth YOY was (21.42%).  The earnings decline was largely a result of non-operational activity.

cbio.png

MNKD: Float of 90.79 million shares with 33.45% short.  Once this begin to up up, it will move quickly due to it massive short interest.  

The Motley Fool just conducted an interview with MNKD's CEO on Sunday.  This could provide the needed catalyst for the next spike in price.  

MNKD.png

Watchlist 11/17/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include:  $CDTI, $CADC, $MRDN

CDTI: Float of 10.12 million shares with 5.76% short.

Q3 Earning released on November 14th.  Milestones in CDTi's development as a provider of enabling technology to the automotive catalyst industry:

  • Completed business realignment with the sale of their downstream distribution activities in the North American aftermarket
  • Secured their first Chinese OEM vehicle platform for their advanced materials
  • Signed a joint development agreement with a major global OEM focused on material systems for catalyst applications.
  • Momentum in China and India has also energized discussions with global OEMs regarding their low PGM catalyst design opportunities.
cdti.png

CADC:  Float of 1.46 million 0.16% short.  

No Catalyst, just another low float Chinese stock probably getting pumped.  Go with it and watch carefully for the top.  Closed near resistance going back to 2014.  IMO, a break of $8.50 may lead it to $11.25.

cadc.png

MRDN:  Float of 8.08 million shares with 1.34% short.

Meridian Innovations Attended and Provided Public Comment at Quarterly Biomass Research and Development Meeting.  Meridian Innovations presented to the Technical Advisory Committee, a group consisting of volunteers from various corporations, universities and non-profit organizations and tasked with the job of advising the Biomass Research and Development Board on areas of focus for their initiative.

Meridian Innovations specifically reviewed the status of its technology portfolio that looks to capitalize on cost-effectively recovering lignin from biomass at small or large scale to greatly expand the revenue potential for existing biomass processing facilities like pulp & paper mills or cellulosic biorefineries. Meridian Innovations believes that the Technical Advisory Committee will benefit heavily from the understanding that its technology portfolio has the ability to generate between 35% and 100% more revenue per ton of biomass in today's biomass processing facilities.

mrdn.png

Watchlist 11/16/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include: $CHFS, $MRDN, $APHB

CHFS: Float of 0.49 million shares with 21.12% short.  Wednesday's volume was 10 million - that's more than 20 times its float of 0.49 million.  The Finviz target price is $25.00.  See attached 5-minute chart.  Many of my technical indicators are reversing back up.  The Relative Momentum Index (RMI) and the Relative Strenght Index (RSI) are not in oversold territory.  The price looks like it wants to cross the green Ichimoku Cloud.  This stock may still have some gas left in its tank.  However, be very cautious If you do trade it.  It needs your full attention.

Potential Catalyst for Wednesday's spike:  November 3rd - Simply Wall St. -   CHF Solutions Inc,  a healthcare equipment and supplies company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last few months, increasing to $15.6 at one point, and dropping to the lows of $6.19. This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price.   If you’ve been keeping an eye on CHFS for a while, now might be the time to enter the stock. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy CHFS.

chfs.png

MRDN:  Float of 8.08 million shares with 1.34% short.  Meridian Waste Solutions, Inc. (NASDAQ: MRDN) ("Meridian Waste" or the "Company"), a vertically integrated, non-hazardous solid waste services company, today reported financial and operational results for the three-month period ended September 30, 2017.

For the three months ended September 30, 2017, revenues were $14.8 million, a 77% increase from $8.4 million for the three months ended September 30, 2016. Organic revenue growth of the Midwest segment of 9.0% was driven by additional customers and price increases. Gross profit improved by $1.5 million to $4.5 million in the three months ended September 30, 2017, as compared to a $3.0 million gross profit in the three months ended September 30, 2016. Operating expenses were $10.4 million or 70% of revenue, for the three months ended September 30, 2017 as compared to $5.4 million, or 64% of revenue, for the three months ended September 30, 2016. This increase is due to increased labor costs in 2017 in the Midwest segment. Operating labor expenses for the 2016 period were 19% of revenues, whereas 2017 expenses are 27% of revenue

mrdn.png

APHB: Float of 8.62 million shares with 15.18% short. A clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announced financial results for the third quarter ended September 30, 2017 on Tuesday.

Highlights:

  • Administered first-in-human intravenous treatment of AB-SA01 for a patient suffering from a life-threatening Staphylococcus aureus (S. aureus) infection of the heart (endocarditis). AB-SA01 was administered intravenously to the patient over two weeks and was well tolerated.
  • Announced publication of a case study detailing the successful treatment of a critically ill patient with a multidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii) infection in the journal Antimicrobial Agents and Chemotherapy in August 2017.

They also presented a company overview at the BIO-Europe 2017 Conference, on Tuesday, November 7, 2017, at CityCube, Berlin, Germany.

aphb.png

Watchlist 11/15/2017

STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES.  STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE.  ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS.  PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).

Stocks highlighted in this watchlist include: $KLIC, $SSKN, $ADMA, $SVRA, ACBFF and CMMDF (both OTC)

KLIC: Float of 70.09 million shares with 1.21% short.  Momentum increasing toward the end of the day.  Down slightly after hours.

Singapore-based Kulicke & Soffa (KLIC) reported earnings per share of 51 cents, up 240% year over year, on sales of $215.9 million, up 48%, in its fiscal fourth quarter ended Sept. 30. Analysts expected earnings of 35 cents a share on sales of $208.7 million.  For the current quarter, it expects sales of $190 million, up 27%, based on the midpoint of its guidance. It did not give a target for earnings per share. Wall Street was modeling earnings per share of 17 cents on sales of $160.7 million.

klic.png

SSKN: Float of 2.47 million shares with 4.85% short.  Finviz price target of $12.00.Third quarter total revenues were $7.5 million, a decrease of 3.7% year-over-year;

A medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, reported financial results for the quarter ended September 30, 2017.  Third quarter total revenues were $7.5 million, a decrease of 3.7% year-over-year as Recurring revenues were negatively impacted by hurricanes in Florida, Georgia, and Texas.  The passing of hurricane season should start to increase Recurring revenues.  The hurricanes decrease the stock price by 40% over 4 weeks. 

sskn.png

ADMA: Float of 11.92 million shares with 0.92% short.

ADMA Biologics experienced its first full quarter merged with the Biotest Therapy Business Unit (BTBU) and reported 3Q:17 results on November 3, 2017.  The main goal and achievement in the quarter was to resume production of Nabi-HB and to make progress addressing the discrepancies in the FDA warning letter.  

adma.png

SVRA: Float of 22.44 million shares with 1.22% short.  

Savara Reports Third Quarter 2017 Financial Results and Provides Business Update. Savara's net loss attributable to common shareholders for the three months ended September 30, 2017 was $6.8 million, or $(.28) per share, compared with a net loss attributable to common shareholders of $3.3 million, or $(1.21) per share, for the third quarter of 2016, which represents the historical financial information of the private company Savara Inc., which completed its merger with Mast Therapeutics, Inc. on April 27, 2017.
 - Anticipating complete enrollment in the Molgradex Phase 3 IMPALA study in Q1 2018- Initiating Phase 2a study of Molgradex for the treatment of NTM in early 201
Expecting top-line results from the Aironite Phase 2 INDIE study in H1 2018

Savara Inc., an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the Jefferies 2017 London Healthcare Conference on Thursday, November 16th, 2017 at 12:40 p.m. Greenwich Mean Time.

svra.png

ACBFF (OTC): Float of 263 million shares and CMMDF Float of 13.7 million shares.  Charts for both companies below.  This could be hugh.

Aurora Cannabis Inc. (ACB) ("Aurora") announced today that it has submitted a proposal (the "Proposal") to acquire all of the issued and outstanding common shares of CanniMed Therapeutics Inc. (CMED) ("CanniMed"). The proposal was delivered to the Board of Directors of CanniMed on November 13, 2017 and Aurora is seeking to pursue a mutually agreed upon combination with CanniMed.
 

All-share Proposal, valued at $24.00 per CanniMed share based on the closing share price of
 Aurora on November 14, 2017, reflects a 56.9% premium over the most recent closing price
 of CanniMed shares on November 14, 2017 Irrevocable lock-up agreements with approximately
38% of CanniMed shareholders to vote in favour of Aurora's proposal or tender to Aurora's 
bid -- The combination would create a global leader in the cannabis industry with a 
pro-forma market capitalization exceeding $3.0 billion --
acbff.png
cmmdf.png
Member Login
Welcome, (First Name)!

Forgot? Show
Log In
Enter Member Area
My Profile Not a member? Sign up. Log Out